Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Novavax NVAX reported first-quarter 2025 earnings of $2.93 per share, which beat the Zacks Consensus Estimate of 71 cents. In the year-ago quarter, the company reported a loss of $1.05 per share.

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...

Novavax (NVAX) closed the most recent trading day at ... At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%. Coming into today, shares of the vaccine maker had gained ...

Novavax (NVAX) closed the most recent trading day at ... Elsewhere, the Dow saw a downswing of 2.48%, while the tech-heavy Nasdaq depreciated by 2.55%. Prior to today's trading, shares of the ...

(RTTNews) - Novavax, Inc. (NVAX) reported net income for the first ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Novavax (NVAX) closed the most recent trading day at ... Meanwhile, the Dow experienced a drop of 0.39%, and the technology-dominated Nasdaq saw a decrease of 0.05%. Shares of the vaccine maker ...

(RTTNews) - Novavax, Inc. (NVAX) said it has updated the terms of ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Novavax NVAX shares rallied 19.5% in the last trading session to close at $7.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

$50,000 of NOVAVAX INC. lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Guidance navigating vaccine policy.

$170,000 of NOVAVAX INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to COVID-19 vaccines ...